FT-12
Phase 1- Indications
- Breast cancer ER+, Prostate cancer
Company intelligence / Profile preview
Finn Therapeutics
Belfast, Northern Ireland, United Kingdomfinntherapeutics.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Phase 1
01
Overview
Finn Therapeutics develops first-in-class biologic therapies—primarily monoclonal antibodies—targeting the tumor microenvironment and mechanisms of resistance/metastasis in cancer. The company leverages deep expertise in oncology drug development, with a focus on diseases with high unmet need. No published clinical results yet; pipeline appears to be at preclinical/early development stage.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Biologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Finn Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Finn Therapeutics.